Official Title
Clinical Course and Treatment of COVID-19 Inpatients in Hospital
Brief Summary

The study is an epidemiological observational study. It serves to collect data from patients with positive COVID-19 test results who are hospitalized. All data describing the course of the inpatient stay are recorded (Length of stay, course of therapy, medication, X-ray and CT results,ventilation mode and duration, laboratory). Furthermore, anthropometric data and information on COVID-19 symptoms is recorded.

Detailed Description

The aim of this study is to describe the course of disease and the treatment of patients
suffering from COVID-19 who are hospitalized and treated as inpatients:

1. Are there common features (previous illnesses, medication, age, BMI, etc.), which may
influence the course of disease?

2. Are there therapeutic procedures that have a positive or negative impact on the course
of the disease or the length of stay in the intensive care unit/ the duration of
ventilation (early/late intubation, CPAP, NIV, ECMO)?

Unknown status
COVID-19
Eligibility Criteria

Inclusion Criteria:

- positive COVID-19 test result

- Age > 18 years

Exclusion Criteria:

- Age < 18 years

- negative COVID-19 test result

- lack of agreement

- Any medical, psychological or other condition, that restricts the ability of the
person to be informed and to give the consent for voluntary participation in this
trial

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
Countries
Germany
Locations

Institut für Pneumologie an der Universität zu Köln / Wissenschaftliches Institut Bethanien für Pneumologie e.V.
Solingen, Nordrhein-Westfalen, Germany

Investigator: Simon Herkenrath
Contact: 0212636662
institut@klinik-bethanien.de

Contacts

Marcel Treml, Dr.
+49212636661
institut@klinik-bethanien.de

Anja Pietzke-Calcagnile, Dr.
+49212636663
institut@klinik-bethanien.de

Winfried Randerath, Prof. Dr., Principal Investigator
Krankenhaus Bethanien Solingen

Wissenschaftliches Institut Bethanien e.V
NCT Number
MeSH Terms
COVID-19
Disease Progression